MicroConstants Welcomes Dr. John Marcelletti as Senior Director of Immunology
SAN DIEGO, CALIFORNIA, September 25, 2015 – MicroConstants is pleased to welcome Dr. John Marcelletti to our team as Senior Director of Immunology. “We are excited to bring John into our family. He brings more than 20 years of drug development experience to the table, with many years directing regulated bioanalytical lab operations (GLP and regulated clinical),” added Gilbert N. Lam, President and Chief Scientific Officer of MicroConstants.
MicroConstants China In-licenses Global Rights of AA98 Antibody Drug Candidates from Institute of Biophysics, Chinese Academy of Sciences
BEIJING, CHINA, January 29, 2015 – MicroConstants China, Inc. announced today that it has signed a licensing agreement to gain the global rights for the development of AA98 antibody drug candidates for the treatment of various cancers, multiple sclerosis (MS), and age related macular degeneration (AMD) from the Institute of Biophysics (IBP), Chinese Academy of Sciences (CAS).
MicroConstants Receives Annual CRO Leadership Award for Achievement in Quality, Regulatory and Innovation
SAN DIEGO, CALIFORNIA, March 12, 2014 – MicroConstants, a Contract Research Organization focused on regulated bioanalysis and DMPK, has received a 2014 CRO Leadership Award in the areas of quality, regulatory and innovation by Life Science Leader, a global life sciences industry magazine
MicroConstants Expands Biomarker Testing and Analysis Services for Preclinical and Clinical Diagnostic Research
Appoints Director of Biomarker Research and Acquires Luminex Platform for Multiplex Assays
SAN DIEGO, CALIFORNIA, June 25, 2013 – MicroConstants, a Contract Research Organization (CRO) specializing in regulated bioanalysis and DMPK, announces the appointment of Doinita Serban, Ph.D. as director of biomarker research to oversee the expansion of biomarker testing and analysis services for preclinical and clinical diagnostic research. Doinita’s extensive experience with biomarker assay development, validation, and profiling of disease panels, coupled with the implementation of the Luminex platform, will enable MicroConstants to broaden their biomarker analysis capabilities to include additional assay formats, such as multiplex immunoassays, gene expression and profiling assays.
MicroConstants Welcomes Pat deLisio as Director of East Coast Business Development
SAN DIEGO, CA, April 2, 2013 – MicroConstants, a regulated bioanalysis and DMPK specialty Contract Research Organization (CRO) in San Diego, California, announces the appointment of Patricia deLisio as their new director of east coast business development. Pat joins MicroConstants’ business development team with more than 12 years of experience selling contract research services to companies in the pharmaceutical, biotech, agrochemical, animal health, and specialty chemical industries. As the director of east coast business development, Pat will be responsible for developing new business opportunities in the region and implementing innovative sales and marketing strategies to help further the company’s mission of becoming the recognized leader in bioanalytical and pharmacokinetic analysis.
FDA Inspects MicroConstants for Compliance with Good Laboratory Practices, No Deficiencies Noted
SAN DIEGO, CA, October 9, 2012 – Bioanalytical and pharmacokinetic specialty Contract Research Organization (CRO) MicroConstants announced today the successful completion of a five-day inspection by the United States Food and Drug Administration (FDA) for compliance with Good Laboratory Practice (GLP) regulations.
On September 20, 2012, an investigator from the FDA visited MicroConstants’ San Diego facility for a routine inspection to assess the CRO’s overall compliance with GLP regulations. During the visit, the investigator toured the facility and laboratory areas and reviewed several method validations, three sample analysis projects, and a pharmacokinetic analysis report. Upon completion of the inspection, the investigator reported zero findings, observations, or recommendations.
MicroConstants China’s New Facility Passes OECD GLP Compliance Inspection
BEIJING, CHINA, August 27, 2012 – MicroConstants China Inc., a Contract Research Organization (CRO) conducting preclinical PK studies and providing full-service early stage clinical trial management in China, has received a renewed Endorsement of Compliance with the OECD Principles of Good Laboratory Practice (GLP) at its newly established facility in Beijing. The Endorsement was initially awarded in May 2011 following an inspection at MicroConstants China’s previous location.
MicroConstants Welcomes a New Immunology Manager and Announces the Expansion of Immunology Services
SAN DIEGO, CA, August 10, 2011 – MicroConstants, Inc., a bioanalytical and pharmacokinetic specialty Contract Research Organization (CRO) in San Diego, announces the appointment of Lilin Wang as the new manager of their Immunology Department. Lilin brings to MicroConstants more than 18 years of experience developing immunological and molecular assays to support preclinical and clinical drug development studies. His expertise will enable the Company to provide additional contract research services to pharmaceutical and biotech companies developing large molecule drugs and other biologics.
MicroConstants China Receives Endorsement of OECD GLP Compliance
BEIJING, CHINA, May 26, 2011 – MicroConstants China Inc., a Contract Research Organization (CRO) conducting preclinical pharmacokinetics studies and providing full-service early stage clinical trial management in Beijing, announces the Endorsement of Compliance with the OECD Principles of Good Laboratory Practice (GLP) in the areas of analytical chemistry and pharmacokinetic studies from the Netherlands GLP Compliance Monitoring Programme. MicroConstants China is the first test facility in China to receive an Endorsement of GLP Compliance from the Netherlands inspectorate.
MicroConstants Completes Installation of Latest LC/MS/MS Technology to Achieve Improved Sensitivity in Bioanalytical Method Development
SAN DIEGO, CA, March 2, 2011 – MicroConstants, Inc., a bioanalytical and pharmacokinetic-specialty Contract Research Organization (CRO) in San Diego, California, announces today that it has successfully completed the installation and qualification of a new Xevo® TQ-S tandem mass spectrometer from Waters Corporation. The unparalleled speed, sensitivity and accuracy of this new LC/MS/MS system will allow MicroConstants to quantify compounds at lower concentrations than previously possible and enable the development of more robust bioanalytical methods for even the most analytically complex compounds.
MicroConstants China Receives CNAS (ISO-17025) Accreditation
BEIJING , CHINA , November 5, 2010 – MicroConstants China Inc., a Contract Research Organization (CRO) specializing in preclinical and clinical pharmacokinetics contract research, announces the accreditation of its bioanalytical laboratory by the China National Accreditation Service for Conformity Assessment (CNAS), a Chinese government agency that monitors quality systems of analytical laboratories based on ISO-17025 guidelines.
MicroConstants Celebrates National Chemistry Week by Teaching San Diego High School Students About the Drug Development Process
SAN DIEGO, CA, October 21, 2010 – In honor of National Chemistry Week (NCW), MicroConstants, a bioanalytical and pharmacokinetic-specialty Contract Research Organization (CRO) in San Diego, California, has joined with Herbert Hoover High School to help raise awareness of the significance of chemistry in our everyday lives.
National Chemistry Week is a community-based annual event organized by the American Chemical Society (ACS) to unite local ACS sections, businesses, schools and individuals in communicating the importance of chemistry to our quality of life. This year, MicroConstants is participating by demonstrating to local high school students the roles that chemistry and chemists play in developing new drugs to fight disease and help improve people’s lives everyday. The goal is to show students at Hoover High that studying chemistry can lead to many exciting careers and opportunities. MicroConstants will also be donating laboratory equipment to Hoover High’s science department to provide students with some of the supplies they need to support their chemistry education.
MicroConstants Expands Its GLP Bioanalytical Capacity and Broadens Business Development Efforts Into the East Coast
SAN DIEGO, CA, June 10, 2010 – MicroConstants, Inc., a bioanalytical and pharmacokinetic-specialty Contract Research Organization (CRO) in San Diego, California , announces the continued expansion of its bioanalytical capacity through the addition of a second Waters Xevo TQ MS system. The CRO has also appointed a new East Coast business development manager to actively pursue new business opportunities in that region.
MicroConstants China Enters Collaboration Agreement with Institute of Zoology, Kunming to Promote Primate Research and Develop Novel Drug Candidates
KUNMING, CHINA, April 30, 2010 – MicroConstants China Inc., a Contract Research Organization (CRO) specializing in preclinical and clinical pharmacokinetics contract research, announces the signing of a collaboration agreement with the Kunming Institute of Zoology (KIZ), Chinese Academy of Science. The agreement will establish a new Technology Commercialization Center of Kunming Institute of Zoology and designates MicroConstants China as the project manager for the development and out-licensing of KIZ’s novel drug candidates globally
MicroConstants Now Offers Nanoparticle Formulation Services
Unveils New Service Offering at the Society of Toxicology’s 2010 Annual Meeting & ToxExpo™
SALT LAKE CITY, UTAH, March 8, 2010 – MicroConstants, a GLP-compliant Contract Research Organization (CRO) specializing in bioanalytical and pharmacokinetic analysis, has acquired access to a new nanosizing technology that transforms water insoluble compounds into nanoparticles, making formulation preparation and dosing for toxicology studies easier. In multiple cases, the method has been proven to increase the gastro-intestinal absorption of highly insoluble compounds ensuring maximal oral exposure for toxicology studies.
MicroConstants China Participates in the NIH Clinical Pharmacology Training Program
David Yang, president of MicroConstants China, discusses regulatory policies, clinical pharmacology and drug development strategy for Chinese biotech companies
BEIJING, CHINA, November 20, 2009 – MicroConstants China Inc., a Contract Research Organization (CRO) specializing in bioanalysis and pharmacokinetics, announces their participation in the National Institute of Health’s (NIH) Principles of Clinical Pharmacology training program in Beijing, China. Dr. Q. David Yang, president of MicroConstants China, was a panelist at the event, and several MicroConstants employees assisted NIH experts by providing translation services during the training program.
MicroConstants Welcomes Ron Shevock as Director of Business Development
SAN DIEGO, CA, November 2, 2009 – MicroConstants, Inc., a San Diego-based Contract Research Organization (CRO), today announced the appointment of Ron Shevock as their new director of business development. Ron, a former business development manager for a pharmaceutical product development company, has extensive experience selling contract research services to pharmaceutical and biotech companies at all stages of drug development.
MicroConstants Announces the USFDA and OECD GLP-Compliance of its Beijing Bioanalytical Facility
BEIJING, CHINA, March 24, 2009 – MicroConstants, Inc., a bioanalytical and pharmacokinetic-specialty Contract Research Organization (CRO) based in San Diego, California, announces today that its Beijing bioanalytical laboratory has met USFDA Good Laboratory Practice (GLP) requirements. MicroConstants China Inc. offers DMPK and bioanalytical contract research services to domestic and international pharmaceutical companies conducting preclinical and clinical studies in China. The establishment of the Beijing bioanalytical lab will eliminate the need for transferring valuable clinical samples across national borders.
MicroConstants Announces the Addition of a QTof LC/MS/MS System
SAN DIEGO, CA, February 4, 2009 – MicroConstants, a bioanalytical and pharmacokinetic-specialty Contract Research Organization (CRO) based in San Diego, California, announces today that it has successfully completed the installation and qualification of a Micromass QTof mass spectrometer system from Waters.